RCC IO Expansion AVEO is actively developing FOTIVDA in immuno-oncology combinations for RCC and other indications, with abstracts accepted for ASCO 2026 signaling ongoing clinical expansion. This creates opportunities for collaborations in IO trials, biomarker development, companion diagnostics, and co-development or commercialization partnerships with CROs and research partners.

Access & Payer AVEO's partnership with Annexus Health highlights a focus on patient access and payer engagement. Opportunities exist to offer patient support programs, reimbursement strategy services, prior authorization optimization, and digital patient assistance platforms aligned with AVEO's commercialization plan.

Clinical Trial Solutions With ongoing IO trial activity and regulated content needs, there is demand for CRO services, clinical operations support, data analytics, real-world evidence programs, and biomarker strategy to accelerate development and post-approval studies.

Commercial Readiness AVEO's revenue scale and growth trajectory point to a sizable commercialization opportunity. As FOTIVDA expands to additional indications and IO combos, there is a need for market access planning, launch readiness, field force optimization, KOL mapping, and digital marketing analytics to maximize market penetration and payer support.

Partnership Potential Strategic partnerships are already in place with NiKang Therapeutics and LG Chem, signaling openness to ecosystem collaborations. There is potential to explore additional licensing, co-development, or regional distribution agreements, particularly leveraging LG Chem's global footprint to reach new geographies and indications through joint ventures or co-promotion deals.